Neurent Medical secures major funding for chronic rhinitis device
Irish medtech startup Neurent Medical has raised €62.5 million in a Series C funding round to accelerate commercialization of its proprietary NEUROMARK system, a minimally invasive solution for patients suffering from chronic rhinitis. The latest investment underscores growing investor confidence in device-based treatments that target underlying nerve pathways rather than relying solely on long-term medication.
Targeting an underserved global patient population
Chronic rhinitis—a condition characterized by persistent nasal congestion, runny nose, and sneezing—affects hundreds of millions of people worldwide. Many patients experience limited relief from traditional therapies such as antihistamines, nasal sprays, or surgery, creating a significant unmet clinical need.
The NEUROMARK system is designed to address this gap by using controlled radiofrequency energy to disrupt hyperactive nerve signals in the nasal cavity. By modulating the activity of these nerves, the device aims to deliver durable symptom relief without the need for continuous drug therapy.
How the NEUROMARK system works
Minimally invasive neuromodulation
NEUROMARK is a single-use, catheter-based device that can be deployed in an outpatient setting. Guided by the treating physician, the system delivers precisely targeted neuromodulation to key nerve clusters associated with nasal hyperreactivity. The procedure is designed to be quick, with minimal downtime, and to integrate seamlessly into existing ear, nose and throat (ENT) clinical workflows.
Regulatory and clinical trajectory
The fresh capital will enable Neurent Medical to expand clinical studies, support regulatory pathways in key markets, and build commercial infrastructure, particularly in Europe and North America. The company is expected to invest heavily in clinical evidence generation, physician training, and reimbursement strategies to position NEUROMARK as a standard-of-care option for appropriate chronic rhinitis patients.
Strengthening Ireland’s medtech innovation footprint
The Series C round further cements Ireland’s reputation as a hub for medical device innovation. With the backing of international investors, Neurent Medical is poised to compete in a rapidly evolving market for minimally invasive ENT therapies, where demand is rising for solutions that improve quality of life while reducing the burden of long-term medication use.
If successfully scaled, NEUROMARK could offer a new therapeutic pathway for millions of chronic rhinitis sufferers who have exhausted conventional treatment options.